ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2559

PRO-Resolving Mediators Issued from Apoptotic CELL Efferocytosis (SUPERMAPO) Modulate Antigen Presenting CELL Properties Toward a Tolerogenic Profile: Efficacy in the Treatment of Collagen- Induced Arthritis

Francis Bonnefoy1, Romain Vallion2, Mélanie Couturier3, Anna Daoui3, Eric Toussirot4 and Sylvain Perruche1, 1UMR1098 INSERM, EFS Bourgogne Franche Comté, Besançon, France, 2INSERM UMR 1098, EFS Bourgogne Franche Comté, Besançon, France, 3INSERM UMR1098, EFS Bourgogne Franche Comté, Besançon, France, 4Service de Rhumatologie, CHU J Minjoz, Besancon, France

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Animal models, Apoptosis, arthritis and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Animal Models Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Pro-resolving mediators produced by macrophages eliminating apoptotic effector cells during the resolution of inflammation have been shown to stop inflammation, favor tissue repair and return to homeostasis. In immune-mediated inflammatory diseases such as rheumatoid arthritis (RA), one may believe that reintroducing proresolving mediators would allow the control of the disease. We have developed a cell culture system of macrophages and apoptotic cells that mimics this phase of resolution. The supernatant of this cell culture system called SuperMApo (SUPERnatant issued from Macrophage APOptotic cell culture) is enriched in pro-resolving factors including anti-inflammatory cytokines like TGF-b.

Objectives: to evaluate the effects of SuperMApo in the treatment of collagen-induced arthritis (CIA).

Methods: SuperMApo is obtained after 48h of culturing macrophages from peritoneal cavity with apoptotic cells obtained from thymus after X-ray irradiation. CIA was used as a model of RA. SuperMApo (200 μL of 5x concentrated SuperMApo,IV, for 2 days) was injected in score 8 CIA mice. The effect of SuperMApo was first evaluated on APC and T cells from naïve mice in terms of phenotype, profile and properties such as maturation of APC before or after TLR-ligand stimulation and T cell polarization assays. Then, SuperMApo was evaluated in vivo in CIA mice.

Results: Macrophages, cDC and pDC submitted to SuperMApo demonstrated robust insensitivity to TLR ligand-induced activation, particularly in terms of co-stimulatory molecules expression. Spleen cells cultured with SuperMApo demonstrated a strong Treg increase. This was confirmed using naïve CD4+CD25– T cells cultured in the presence of SuperMApo showing Foxp3 expression. CIA mice received 2 injections of SuperMApo (over 48h) and demonstrated a significant long term decrease of CIA (joint score before and after SuperMApo: 8-10 and 1-4, respectively; sustained response to 60 days). This clinical improvement was associated with a higher suppressive function of Treg. Treg transfer from mice treated by SuperMApo to arthritic mice induced joint improvement. Finally, we tested SuperMApo effect on PBMC issued from 4 patients with RA, with and without TLR ligand activation. Our results were that monocytes from 3 patients showed a decreased inflammatory phenotype after overnight exposure to SuperMApo (CD80, CD86, CD40 and HLA-DR expression).

Conclusion: these data demonstrated that macrophages eliminating apoptotic cells produced pro-resolving mediators affecting Antigen Presenting Cell properties therefore allowing the control of arthritis in the CIA model


Disclosure: F. Bonnefoy, None; R. Vallion, None; M. Couturier, None; A. Daoui, None; E. Toussirot, None; S. Perruche, None.

To cite this abstract in AMA style:

Bonnefoy F, Vallion R, Couturier M, Daoui A, Toussirot E, Perruche S. PRO-Resolving Mediators Issued from Apoptotic CELL Efferocytosis (SUPERMAPO) Modulate Antigen Presenting CELL Properties Toward a Tolerogenic Profile: Efficacy in the Treatment of Collagen- Induced Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/pro-resolving-mediators-issued-from-apoptotic-cell-efferocytosis-supermapo-modulate-antigen-presenting-cell-properties-toward-a-tolerogenic-profile-efficacy-in-the-treatment-of-collagen-induced-ar/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pro-resolving-mediators-issued-from-apoptotic-cell-efferocytosis-supermapo-modulate-antigen-presenting-cell-properties-toward-a-tolerogenic-profile-efficacy-in-the-treatment-of-collagen-induced-ar/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology